TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 17290455

Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A (BTX‐A) 150 IU injected into calf muscles
Number of subjects: 11

Group type: COMPARATOR
Intervention: Normal saline injected into calf muscles
Number of subjects: 11
Study: 15486365

Group type: EXPERIMENTAL
Intervention: Intensive oral care (teeth and gingiva cleaned after every meal for 1 month)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Control group (performed their own oral care for 1 month)
Number of subjects: 59
Study: 16519422

Group type: EXPERIMENTAL
Intervention: Motor cortex stimulation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 9758291

Group type: EXPERIMENTAL
Intervention: Trovafloxacin 200 mg once daily
Number of subjects: 312

Group type: COMPARATOR
Intervention: Amoxicillin 1 g three times daily
Number of subjects: 312
Study: 7532763

Group type: EXPERIMENTAL
Intervention: Anipamil 80 mg once daily
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Anipamil 160 mg once daily
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 2703617

Group type: EXPERIMENTAL
Intervention: Ventricular fibrillation duration of 10 s
Number of subjects: 10

Group type: COMPARATOR
Intervention: Ventricular fibrillation duration of 20 s
Number of subjects: 10
Study: 356718

Group type: EXPERIMENTAL
Intervention: Salbutamol with theophylline and hydroxyzine
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Ephedrine with theophylline and hydroxyzine
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Theophylline and hydroxyzine (basic combination)
Number of subjects: 16
Study: 31410659

Group type: EXPERIMENTAL
Intervention: Febuxostat therapy
Number of subjects: 370

Group type: COMPARATOR
Intervention: No application of febuxostat therapy
Number of subjects: 370
Study: 28492898

Group type: EXPERIMENTAL
Intervention: selumetinib + docetaxel
Number of subjects: 510

Group type: COMPARATOR
Intervention: placebo + docetaxel
Number of subjects: 510
Study: 23622873

Group type: EXPERIMENTAL
Intervention: Geographic atrophy lesions in untreated eyes
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Development of GA
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: GA formed in areas previously occupied by drusenoid pigment epithelial detachments
Number of subjects: 114
Study: 22676840

Group type: EXPERIMENTAL
Intervention: Exposure to TCTT campaign messages
Number of subjects: 0

Group type: COMPARATOR
Intervention: No exposure to campaign messages
Number of subjects: 0
Study: 20659103

Group type: EXPERIMENTAL
Intervention: 45° seated position
Number of subjects: 40

Group type: COMPARATOR
Intervention: Supine position
Number of subjects: 40
Study: 17980179

Group type: EXPERIMENTAL
Intervention: Patient-controlled analgesia (PCA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Scheduled intermittent intravenous (i.v.) hydromorphone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Scheduled intermittent subcutaneous (s.q.) hydromorphone
Number of subjects: 0
Study: 15741468

Group type: EXPERIMENTAL
Intervention: Errorless learning
Number of subjects: 60

Group type: COMPARATOR
Intervention: Symptom management
Number of subjects: 60
Study: 11894727

Group type: EXPERIMENTAL
Intervention: Intensive physical therapy (3.6 hours/week)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Control group (1.9 hours/week)
Number of subjects: 88
Study: 10622051

Group type: EXPERIMENTAL
Intervention: Chlamydia antigen positive in patients with non-bacterial prostatitis
Number of subjects: 55

Group type: COMPARATOR
Intervention: Chlamydia antigen positive in control group
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Treatment with doxycycline 100 mg twice daily for 10 days
Number of subjects: 55
Study: 7865201

Group type: EXPERIMENTAL
Intervention: Parental acceptance of proposed aversive behavioral intervention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Parental rejection of proposed aversive behavioral intervention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Judges' consideration of client's rights
Number of subjects: 0
Study: 2913892

Group type: EXPERIMENTAL
Intervention: Twice-daily theophylline preparation
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Once-daily theophylline preparation
Number of subjects: 16
Study: 132901

Group type: EXPERIMENTAL
Intervention: Topical tetracycline hydrochloride and orally administered lactose capsules
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Orally administered tetracycline hydrochloride and topically applied placebo liquid
Number of subjects: 75

Group type: COMPARATOR
Intervention: Topically applied placebo liquid and orally administered tetracycline hydrochloride
Number of subjects: 75
Study: 31699436

Group type: EXPERIMENTAL
Intervention: Cryoablation
Number of subjects: 35

Group type: COMPARATOR
Intervention: Epidural (EPI)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Patient-Controlled Analgesia (PCA)
Number of subjects: 35
Study: 30696491

Group type: EXPERIMENTAL
Intervention: Virtual reality gait training (VRT)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Non-virtual reality gait training (non-VRT)
Number of subjects: 50
Study: 27908689

Group type: EXPERIMENTAL
Intervention: PCSK9 genetic variants (rs11583680, rs11591147, rs2479409, rs11206510) scaled to 1 mmol/L lower LDL cholesterol
Number of subjects: 556000
Study: 25181297

Group type: EXPERIMENTAL
Intervention: Treatment for regular past tense, one-hour play-based sessions, once weekly for eight weeks
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Treatment for regular past tense
Number of subjects: 5
Study: 23458447

Group type: EXPERIMENTAL
Intervention: Fibrin glue (TISSEEL) applied to anastomoses
Number of subjects: 57

Group type: COMPARATOR
Intervention: Control group (no fibrin glue)
Number of subjects: 57
Study: 21809068

Group type: EXPERIMENTAL
Intervention: Laser surgery with biostimulation (Er:YAG laser, 200 mJ, 20 Hz, Nd:YAG laser for biostimulation)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Conventional surgery
Number of subjects: 20
Study: 19019342

Group type: EXPERIMENTAL
Intervention: Modified AMT suturing technique (group 1, 21 patients)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Standard AMT suturing to the cornea (group 2, 18 patients)
Number of subjects: 39
Study: 17026815

Group type: EXPERIMENTAL
Intervention: Gemcitabine 1250 mg/m² on days 1 and 8 plus carboplatin AUC 5 on day 1
Number of subjects: 158

Group type: COMPARATOR
Intervention: Carboplatin AUC 2.5 on days 1 and 8
Number of subjects: 158
Study: 12928833

Group type: EXPERIMENTAL
Intervention: 6 degrees head-down bed rest for 14 days
Number of subjects: 11
Study: 11126695

Group type: EXPERIMENTAL
Intervention: Megatrial interventions (specific interventions not mentioned)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Randomised treatment allocation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Large-scale randomised controlled clinical trials (RCT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Smaller explanatory trials or sub-studies
Number of subjects: 0
Study: 8989012

Group type: EXPERIMENTAL
Intervention: Fentanyl 1.5 micrograms/kg intravenous (i.v.) administration
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo administration
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Fentanyl during pain stimulation
Number of subjects: 9
Study: 8452180

Group type: EXPERIMENTAL
Intervention: Fleroxacin 400 mg daily for 7 days
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: Fleroxacin 400 mg daily for 14 days
Number of subjects: 184

Group type: COMPARATOR
Intervention: Chloramphenicol 50 mg/kg per day for 14 days
Number of subjects: 184
Study: 3088648

Group type: EXPERIMENTAL
Intervention: Naloxone (0.0625, 0.25, 1.0, or 4.0 mg/kg)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Naloxone
Number of subjects: 7
Study: 31804005

Group type: EXPERIMENTAL
Intervention: Complicated grief therapy (CGT) with citalopram
Number of subjects: 394

Group type: EXPERIMENTAL
Intervention: Complicated grief therapy (CGT) with placebo
Number of subjects: 394

Group type: COMPARATOR
Intervention: Citalopram alone
Number of subjects: 394

Group type: COMPARATOR
Intervention: Placebo alone
Number of subjects: 394
Study: 30104147

Group type: EXPERIMENTAL
Intervention: One-stage ADM-assisted IBBR
Number of subjects: 142

Group type: COMPARATOR
Intervention: Two-stage IBBR
Number of subjects: 142
Study: 26893405

Group type: EXPERIMENTAL
Intervention: Fibrinogen concentrate
Number of subjects: 116

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 116
Study: 24619608

Group type: EXPERIMENTAL
Intervention: Brace treatment (Br group)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Observation alone (Ob group)
Number of subjects: 54
Study: 21592809

Group type: EXPERIMENTAL
Intervention: Intra-operative device closure (group I)
Number of subjects: 252

Group type: COMPARATOR
Intervention: Surgical closure (group II)
Number of subjects: 252
Study: 19701691

Group type: EXPERIMENTAL
Intervention: Group BMP (Behavioral Modification Program)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 44
Study: 16652130

Group type: EXPERIMENTAL
Intervention: bioactive supplement (n=57)
Number of subjects: 80

Group type: COMPARATOR
Intervention: placebo (n=23)
Number of subjects: 80
Study: 15827356

Group type: EXPERIMENTAL
Intervention: Drain placed at the donor site for 24 hours
Number of subjects: 34

Group type: COMPARATOR
Intervention: No drain at the donor site
Number of subjects: 34
Study: 11834192

Group type: EXPERIMENTAL
Intervention: Olanzapine (OLZ) 2.5 or 5.0 mg daily
Number of subjects: 10
Study: 10207236

Group type: EXPERIMENTAL
Intervention: Partially gastrectomized patients
Number of subjects: 2

Group type: COMPARATOR
Intervention: Control group (age-matched individuals not subjected to gastric surgery)
Number of subjects: 2
Study: 7882472

Group type: EXPERIMENTAL
Intervention: Thrombolytic therapy
Number of subjects: 41021

Group type: EXPERIMENTAL
Intervention: Age < 45 years
Number of subjects: 41021

Group type: EXPERIMENTAL
Intervention: Age > 75 years
Number of subjects: 41021

Group type: EXPERIMENTAL
Intervention: Lower systolic blood pressure
Number of subjects: 41021

Group type: EXPERIMENTAL
Intervention: Higher Killip class
Number of subjects: 41021

Group type: EXPERIMENTAL
Intervention: Elevated heart rate
Number of subjects: 41021

Group type: EXPERIMENTAL
Intervention: Anterior infarction
Number of subjects: 41021
Study: 2083044

Group type: EXPERIMENTAL
Intervention: Dentifrice containing 0.3% triclosan and 2.0% copolymer in a 0.243% sodium fluoride/silica base
Number of subjects: 79

Group type: COMPARATOR
Intervention: Placebo dentifrice containing 0.243% sodium fluoride in a silica base
Number of subjects: 79
Study: 314777

Group type: EXPERIMENTAL
Intervention: High-dosage ampicillin (400 mg/kg per day)
Number of subjects: 172

Group type: COMPARATOR
Intervention: Low-dosage ampicillin (150 mg/kg per day)
Number of subjects: 172
Study: 31888701

Group type: EXPERIMENTAL
Intervention: Combination of male-focused mobilization, community-based mobile HIV testing services, and a small incentive.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Male-focused mobilization and testing strategies.
Number of subjects: 0
Study: 28390417

Group type: EXPERIMENTAL
Intervention: Standard cognitive‐behavioral smoking cessation treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Standard cognitive‐behavioral smoking cessation treatment plus behavioral activation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Three-month delayed treatment control group
Number of subjects: 0
Study: 25837839

Group type: EXPERIMENTAL
Intervention: EP2006 (biosimilar filgrastim)
Number of subjects: 0

Group type: COMPARATOR
Intervention: US‐approved originator filgrastim
Number of subjects: 0
Study: 24103384

Group type: EXPERIMENTAL
Intervention: Telemonitoring guided home-based training program
Number of subjects: 0

Group type: COMPARATOR
Intervention: Regular centre-based training program
Number of subjects: 0
Study: 21372490

Group type: EXPERIMENTAL
Intervention: Total Parenteral Nutrition (TPN)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Enteral Nutrition (EN)
Number of subjects: 30
Study: 19335527

Group type: EXPERIMENTAL
Intervention: Breast-feeding with skin-to-skin contact during immunization injections
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group (routine immunization without breast-feeding)
Number of subjects: 120
Study: 16132779

Group type: EXPERIMENTAL
Intervention: Erythropoietin (EPO) therapy at a dose of 2000 U subcutaneously thrice weekly
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (parenteral iron only)
Number of subjects: 40
Study: 12458867

Group type: EXPERIMENTAL
Intervention: Intraoperative arcuate keratotomy with phacoemulsification in the steeper meridian (arcuate keratotomy group)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Phacoemulsification in the steeper meridian without arcuate keratotomy (control group)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Comparison between arcuate keratotomy group and control group
Number of subjects: 34
Study: 10606486

Group type: EXPERIMENTAL
Intervention: Timeline Follow back method (TLFB)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Graduated frequency measure
Number of subjects: 95
Study: 7489472

Group type: EXPERIMENTAL
Intervention: Morphine 50 or 100 micrograms.kg‐1
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Buprenorphine 1.5 or 3.0 micrograms.kg‐1
Number of subjects: 56

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 56
Study: 2006566

Group type: EXPERIMENTAL
Intervention: Lovastatin 40 mg daily for 30 days
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 6754505

Group type: EXPERIMENTAL
Intervention: Gentamicin otic solution (0.3%)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Colistin-neomycin-hydrocortisone otic suspension (colistin 0.3%, neomycin 0.33%, hydrocortisone 1.0%)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 55
Study: 30606151

Group type: EXPERIMENTAL
Intervention: Alcohol-based hand rub (ABHR) used from birth to 3 months postnatally, guided by the 'Newborn Moments for Hand Hygiene in the Home' poster.
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Use of the 'Newborn Moments for Hand Hygiene in the Home' poster.
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Adaptation of the WHO Moments for Hand Hygiene poster into a sticker format on the ABHR bottle.
Number of subjects: 55
Study: 28728599

Group type: EXPERIMENTAL
Intervention: CinnoRA® (40 mg subcutaneous injections every other week)
Number of subjects: 136

Group type: COMPARATOR
Intervention: Humira® (40 mg subcutaneous injections every other week)
Number of subjects: 136
Study: 25738603

Group type: EXPERIMENTAL
Intervention: a‐tDCS of M1
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: a‐tDCS of S1
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: a‐tDCS of DLPFC
Number of subjects: 12

Group type: COMPARATOR
Intervention: Sham a‐tDCS
Number of subjects: 12

Group type: COMPARATOR
Intervention: No‐tDCS
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: a‐tDCS of M1, S1, and DLPFC
Number of subjects: 12
Study: 24835842

Group type: EXPERIMENTAL
Intervention: Isoniazid preventive therapy
Number of subjects: 1329

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1329
Study: 21761403

Group type: EXPERIMENTAL
Intervention: WBI + RS
Number of subjects: 152

Group type: COMPARATOR
Intervention: NR + WBI
Number of subjects: 152
Study: 19752378

Group type: EXPERIMENTAL
Intervention: Homograft aortic root replacement
Number of subjects: 166

Group type: COMPARATOR
Intervention: Freestyle aortic root replacement
Number of subjects: 166
Study: 17464615

Group type: EXPERIMENTAL
Intervention: US-guided injection
Number of subjects: 20

Group type: COMPARATOR
Intervention: Blind injection
Number of subjects: 20
Study: 15220729

Group type: EXPERIMENTAL
Intervention: Amniotic membrane transplantation (AM group)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Conjunctival autograft (CG group)
Number of subjects: 86
Study: 12176948

Group type: EXPERIMENTAL
Intervention: Simvastatin 80 mg monotherapy for 2 years
Number of subjects: 327
Study: 9639238

Group type: EXPERIMENTAL
Intervention: Regular gum
Number of subjects: 20

Group type: COMPARATOR
Intervention: Gum base
Number of subjects: 20
Study: 7857504

Group type: EXPERIMENTAL
Intervention: 900 mg of hypericum per day combined with bright light therapy (3000 lux)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 900 mg of hypericum per day combined with dim light therapy (< 300 lux)
Number of subjects: 20
Study: 2766723

Group type: EXPERIMENTAL
Intervention: 75 micrograms of gestodene combined with 30 micrograms ethinylestradiol as tablet
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: 75 micrograms of gestodene combined with 30 micrograms ethinylestradiol as coated tablet
Number of subjects: 6
Study: 791872

Group type: EXPERIMENTAL
Intervention: Desoxymethasone
Number of subjects: 50

Group type: COMPARATOR
Intervention: Betamethasone valerate
Number of subjects: 50
Study: 30623857

Group type: EXPERIMENTAL
Intervention: Atorvastatin
Number of subjects: 69

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69
Study: 27889299

Group type: EXPERIMENTAL
Intervention: Belatacept
Number of subjects: 173

Group type: COMPARATOR
Intervention: CNI
Number of subjects: 173
Study: 25265887

Group type: EXPERIMENTAL
Intervention: Moderate parenteral sedation and paracervical block
Number of subjects: 56

Group type: COMPARATOR
Intervention: General anesthesia
Number of subjects: 56
Study: 22816679

Group type: EXPERIMENTAL
Intervention: Yogurt beverage providing 4 g of phytosterols per day
Number of subjects: 108

Group type: COMPARATOR
Intervention: Yogurt beverage without phytosterols (placebo)
Number of subjects: 108
Study: 21226129

Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction (MBSR)
Number of subjects: 8
Study: 18632210

Group type: EXPERIMENTAL
Intervention: Smoking-related weight control expectancies
Number of subjects: 755
Study: 17542117

Group type: EXPERIMENTAL
Intervention: Nutrition education for 2 months (face-to-face sessions, group discussions, pamphlets)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no nutrition education)
Number of subjects: 60
Study: 14677218

Group type: EXPERIMENTAL
Intervention: Sensorimotor training; motor learning training with imagery; electrical stimulation (alone or combined with biofeedback); engaging in repetitive, novel tasks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Careful handling; electrical stimulation; movement with elevation; strapping; avoidance of overhead pulleys
Number of subjects: 0
Study: 11061779

Group type: EXPERIMENTAL
Intervention: Physical Activity (PA) program (n = 16)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control (C) program (n = 16)
Number of subjects: 32
Study: 8899078

Group type: EXPERIMENTAL
Intervention: Sucrose polyester (50 g as a single drink)
Number of subjects: 0
Study: 1900605

Group type: EXPERIMENTAL
Intervention: Modified Rambo meatoplasty during translabyrinthine tumor removal
Number of subjects: 50

Group type: COMPARATOR
Intervention: Obstruction of the tympanic orifice of the eustachian tube through the facial recess
Number of subjects: 50
Study: 6679229

Group type: EXPERIMENTAL
Intervention: Verapamil (IV administration, bolus of 0.075 mg/kg up to 5 mg)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Verapamil (IV administration)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Oral drug therapy
Number of subjects: 17
Study: 31380699

Group type: EXPERIMENTAL
Intervention: Acceptance-enhanced behavior therapy for TTM
Number of subjects: 0

Group type: COMPARATOR
Intervention: Psychoeducation and supportive control condition
Number of subjects: 0
Study: 27933703

Group type: EXPERIMENTAL
Intervention: Therapeutic CPAP for 3 months
Number of subjects: 90

Group type: COMPARATOR
Intervention: Subtherapeutic CPAP for 3 months
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Therapeutic CPAP
Number of subjects: 90

Group type: COMPARATOR
Intervention: Subtherapeutic CPAP
Number of subjects: 90
Study: 25721551

Group type: EXPERIMENTAL
Intervention: tDCS
Number of subjects: 19

Group type: COMPARATOR
Intervention: Sham
Number of subjects: 19
Study: 24858834

Group type: EXPERIMENTAL
Intervention: Carbohydrate (CHO) mouth rinse
Number of subjects: 10

Group type: COMPARATOR
Intervention: Taste-matched placebo (PLA) mouth rinse
Number of subjects: 10
Study: 23049087

Group type: COMPARATOR
Intervention: Healthy subjects at 20 Hz
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Stargardt's disease at 20 Hz
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Primary open‐angle glaucoma at 20 Hz
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Nonarteritic anterior ischemic optic neuropathy at 20 Hz
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Retinitis pigmentosa at 20 Hz
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Retinal artery occlusion at 20 Hz
Number of subjects: 117

Group type: COMPARATOR
Intervention: Test-retest difference in healthy group at 20 Hz
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Test-retest difference in disease groups at 20 Hz
Number of subjects: 117
Study: 19720927

Group type: EXPERIMENTAL
Intervention: Bevacizumab 10 mg/kg alone
Number of subjects: 167

Group type: EXPERIMENTAL
Intervention: Bevacizumab plus irinotecan 340 mg/m2 or 125 mg/m2
Number of subjects: 167
Study: 17471998

Group type: EXPERIMENTAL
Intervention: Prolit
Number of subjects: 20

Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 20
Study: 15186955

Group type: EXPERIMENTAL
Intervention: Wine
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Gin
Number of subjects: 40
Study: 12365881

Group type: EXPERIMENTAL
Intervention: Compensated Work Therapy (CWT)
Number of subjects: 142

Group type: COMPARATOR
Intervention: Control
Number of subjects: 142
Study: 11345379

Group type: EXPERIMENTAL
Intervention: Subthreshold stimulation (STS) guided slow pathway (SP) ablation
Number of subjects: 100

Group type: COMPARATOR
Intervention: Conventional criteria for SP ablation
Number of subjects: 100
Study: 9000658

Group type: EXPERIMENTAL
Intervention: MMF 2 g
Number of subjects: 1493

Group type: EXPERIMENTAL
Intervention: MMF 3 g
Number of subjects: 1493

Group type: COMPARATOR
Intervention: PLA/AZA
Number of subjects: 1493

Group type: EXPERIMENTAL
Intervention: MMF 2 g and MMF 3 g
Number of subjects: 1493
Study: 8517509

Group type: EXPERIMENTAL
Intervention: Hypoxic mixture
Number of subjects: 24

Group type: COMPARATOR
Intervention: Air
Number of subjects: 24